Company news
Pfizer, Inc. (NYSE:PFE) news
Every Pfizer, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
September 22, 2026
Health Canada Authorizes Pfizer and BioNTech's Omicron XFG-Adapted COVID-19 Vaccine
September 17, 2026
NCCN Announces Awards for Quality Improvement Initiatives for Metastatic Prostate Cancer (mPCA)
September 14, 2026
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
August 27, 2026
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
August 14, 2026
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
August 4, 2026
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
July 30, 2026
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
July 29, 2026
Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
July 27, 2026
FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
July 22, 2026
Bluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies
July 22, 2026
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
July 10, 2026
Pfizer Declares Third-Quarter 2026 Dividend
June 24, 2026
Pfizer : FDA Approves Pfizer’s IBRANCE Regimen for HR , HER2 Metastatic Breast Cancer Frontline Maintenance
June 24, 2026
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
June 24, 2026
Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
June 23, 2026
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
June 22, 2026
Pfizer Announces Chief Financial Officer Transition
June 18, 2026
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
June 8, 2026
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
June 6, 2026
US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for TALZENNA® (talazoparib) in Combination with XTANDI® (enzalutamide) to Identify Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
June 1, 2026
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
May 31, 2026
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
May 29, 2026
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
May 28, 2026
Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer
May 20, 2026
Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
May 20, 2026
Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
May 18, 2026
OXBRYTA Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
May 15, 2026
European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
May 13, 2026
Refacto (Pfizer) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
May 11, 2026
Atgam (Pfizer) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
May 11, 2026
Giants of Cancer Care® announces the 14th annual class of inductees
May 8, 2026
For the Reasons that Matter: A Multi-Spotlight Campaign Puts Adult Respiratory Health in Focus
May 7, 2026
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
May 5, 2026
MTS Health Partners Appoints Sally Susman as Senior Advisor
May 4, 2026
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
May 4, 2026
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 1, 2026
$4+ Billion OTC Dry Eye Drops Market Analysis Report 2026: Pfizer, Johnson & Johnson Services, and Novartis International Dominate
April 30, 2026
For the Reasons that Matter: A First‑of‑Its‑Kind Multi-Country Campaign Spotlights Adult Respiratory Health
April 30, 2026
Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
April 29, 2026
Pfizer Reaches Three Settlement Agreements for VYNDAMAX
April 28, 2026
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
April 27, 2026
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
April 27, 2026
Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon Biologics
April 24, 2026
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
April 23, 2026
Pfizer Declares Second-Quarter 2026 Dividend
April 22, 2026
Drug Delivery Devices Market Insights, Competitive Landscape, and Forecast Report 2025-2032 - Growing Use of Biologics and Biosimilars, Technological Advancements, and Active Product Developments
April 22, 2026
Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
April 21, 2026
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
April 20, 2026
Frontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of Directors
April 13, 2026